I had two patients who were on dasatinib and L asparginase during induction phase of B ALL treatment develop acute pancreatitis. Is it likely that dasatinib enhances the chance of developing acute pancreatitis if also on L asparginase?
For clarity, both patients developed symptoms such as severe abdominal pain, had abnormal pancreatic enzymes and positive ultrasonography.
Case 1 is 13 yrs female, B-ALL Ph+; case 2 is 46 yrs female, B-ALL Ph+.
The pancreatitis developed during induction in both patients.
Coagulation tests were within normal range in both patients.